Henlius | 复宏汉霖

BioTech/Drugs - Shanghai, Shanghai, CN

Henlius | 复宏汉霖 Employees
Maowei Chen

Head of Manufacturing Science and Technology

Contact Maowei Chen

Carrie Zhang

Head of Data Science Center

Contact Carrie Zhang

Kurt Yu

VP of Marketing & Commercial Operation

Contact Kurt Yu

Leo Ma

Clinical QA Manager

Contact Leo Ma

Bin Gao

Senior Manager, CMC Project Management

Contact Bin Gao

Wendy Wu

HR Director - HRBP

Contact Wendy Wu

Kitty Wu

Talent Acquisition Associate Director

Contact Kitty Wu

View All Henlius | 复宏汉霖 Employees Contact All Henlius | 复宏汉霖 Employees
Henlius | 复宏汉霖 Senior Management
Vanessa Zhang

Executive Assistant to CEO & President

Contact Vanessa Zhang

Jifeng Zhang

Chief Technology Officer and Senior Vice President

Contact Jifeng Zhang

View All Henlius | 复宏汉霖 Employees Contact All Henlius | 复宏汉霖 Employees
Henlius | 复宏汉霖 Details

Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable, and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases, and ophthalmic diseases. Up to date, 6 products have been launched in China, 3 has been approved for marketing in overseas markets, 24 indications are approved worldwide, and 3 marketing applications have been accepted for review in China, the U.S. and EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering over 20 innovative monoclonal antibodies (mAbs) and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as backbone. Apart from the launched products HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in U.S., Zercepac® in Europe) , the first China-developed mAb biosimilar approved in China, U.S. and Europe, HANDAYUAN (adalimumab) and HANBEITAI (bevacizumab), HANSIZHUANG has been approved by the NMPA for the treatment of MSI-H solid tumors, sqNSCLC, ES-SCLC, and ESCC, making it the world’s first anti-PD-1 mAb for the first-line treatment of SCLC. Its NDA for the treatment of nsNSCLC is under review. What's more, Henlius has conduct over 30 clinical studies for 16 products globally, expanding its presence in major markets as well as emerging markets.

Henlius | 复宏汉霖 logo, Henlius | 复宏汉霖 contact details
Employees: 500 - 999
HQ: (510) 445-0305
Location: Shanghai, Shanghai, CN
Revenue: $5.8 million
Biopharmaceuticals Cancer Drugs Global Clinical Trials
Henlius | 复宏汉霖 Technologies
Frameworks and Programming Languages

ASP.NET

CSS and JavaScript Libraries

Bootstrap Framework

Other

Mobile Friendly

View All Technologies Used At Henlius | 复宏汉霖

Contacting Henlius | 复宏汉霖: Connect with Executives and Employees

Get in Touch with Henlius | 复宏汉霖 Executives and Employees

Connecting with Henlius | 复宏汉霖's Executives and Workforce

Accessing Contact Information for Henlius | 复宏汉霖 Executives

Connecting with Henlius | 复宏汉霖: Reach Out to Their Team

Discover How to Contact Henlius | 复宏汉霖 Executives and Staff

Looking to connect with Henlius | 复宏汉霖 executives or employees?

Seeking to Get in Touch with Henlius | 复宏汉霖 Executives or Staff?

Want to Reach Out to Henlius | 复宏汉霖 Executives or Team Members?

In Search of Contact Details for Henlius | 复宏汉霖 Professionals?

Connecting with Henlius | 复宏汉霖: Contacting Executives and Staff

Browse companies
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z